Aethlon Medical, Inc. (OTCMKTS:AEMD) Hesitates Around The 50 Cent Mark

[[tagnumber 0]][[tagnumber 1]]The run of Aethlon Medical, Inc. (OTCMKTS:AEMD) has slowed down recently, but the volumes the company stock is recording are still significant after the steep climb up the charts that the ticker experienced throughout November.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]One reason for the recent hesitation that we see in [[tagnumber 6]]AEMD’s [[tagnumber 7]]movements might be the inflated market cap of $150 million that the company currently commands. When we say inflated, we don’t mean that the news are not good, it’s just that the numbers recorded in the company’s latest filing don’t exactly back up its market value.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Here are the ones of prime interest contained in [[tagnumber 6]]AEMD’s [[tagnumber 7]]balance sheet for the period ended September 30.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 17]] [[tagnumber 18]]cash: $526 thousand[[tagnumber 19]] [[tagnumber 18]]current assets: $892 thousand[[tagnumber 19]] [[tagnumber 18]]total assets: $1 million[[tagnumber 19]] [[tagnumber 18]]current liabilities: $3.38 million[[tagnumber 19]] [[tagnumber 18]]total liabilities: $4.37 million[[tagnumber 19]] [[tagnumber 18]]quarterly revenues: $479 thousand[[tagnumber 19]] [[tagnumber 18]]operating loss: $601 thousand[[tagnumber 19]] [[tagnumber 32]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]On the good side, on November 26 [[tagnumber 6]]AEMD [[tagnumber 7]]announced that they were getting $3.3 million in financing from an equity investment which will be used for “[[tagnumber 38]]clinical advancement of the Aethlon Hemopurifier®, debt reduction and general corporate purposes[[tagnumber 39]]”. On the not–so–good side, the institutional investor that will provide the financing will receive one common share priced at $0.30 and one and one–fifth of a common share purchase warrant, which would allow the investor to receive one common share at a price of $0.30 for every whole warrant.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]][[tagnumber 44]][[tagnumber 45]]The fact that these shares are well below the current price of [[tagnumber 6]]AEMD [[tagnumber 7]]may be the reason for the recent decline of the stock, despite the positive news. Yesterday the company announced that there were positive results from the treatment of patients with Hepatitis C at the Medanta Medicity Institute in India.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Still, the price dropped 7.59% during the session on a hefty volume. There were a total of 12.57 million shares that changed their owners, as the ticker was sliding to a close at $0.5101, that generated $7.22 million in daily trade value.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Today the ticker is still sliding and only time will tell if it will see another red session. In any case, it is imperative that you do your due diligence and weigh out the risks before putting any money on the line.[[tagnumber 2]]